HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Push For Separate US Food Agency Could Grow From Independent Panel’s ‘Urgent’ Call For Change

Executive Summary

As latest evidence supporting their preference, lawmakers and other proponents of moving regulation of food manufacturing and marketing out of FDA and into a separate agency will reference report from panel appointed by Reagan-Udall Foundation at FDA Commissioner Robert Califf’s request.

You may also be interested in...



Congress Boosts FDA Food Safety Budget Nearly $700M, Orders Reports On Formula Supply

Appropriators are “concerned by the fragility of the infant formula supply chain and the detrimental health impacts that can arise from shortage of these regulated products.” Their report published with FY2023 omnibus appropriations also asks for list of Russian firms with pending NDAs, including OTCs.

US Extends Enforcement Discretion For Infant Formula Production With Guidance For Compliance

Guidance extends through Jan. 6 enforcement discretion for formula products cleared for sales under temporary guidance FDA announced in May. Further extensions possible for firms taking steps toward lawful marketing of products in US, agency says.

External Evaluation For US FDA Food Safety ‘Structure, Function, Funding and Leadership’

Members of Congress won’t find mention of criticism of FDA food safety oversight linked most recently to infant formula shortage in Commissioner Califf's announcement. He also didn’t refer to the formula shortage.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153189

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel